Moxostad (Moxonidine)

Moxonidine, the active ingredient in Moxostad, is an imidazoline receptor agonist presented as an oral tablet for systemic use. It is indicated for the management of hypertension in adult patients, where it lowers elevated blood pressure by reducing sympathetic nervous system activity through central imidazoline I1 receptors.

GNH USA supplies Moxostad as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, pharmacies and clinics worldwide under strict quality‑assurance standards. The company adheres to WHO GMP guidelines and offers reliable logistics for global distribution.

Moxonidine is used to treat hypertension, a condition characterized by elevated arterial pressure.

- Hypertension: lowers both systolic and diastolic blood pressure in adults with primary hypertension, helping achieve target values. - Resistant hypertension: can be combined with other antihypertensives when blood pressure remains above goal despite three drugs, including a diuretic. - Isolated systolic hypertension: effective in older patients where systolic pressure predominates, contributing to reduced pulse pressure.

Moxonidine may cause a range of adverse reactions, most of which are mild and reversible.

Common Side Effects: - Dry mouth: sensation of oral dryness. - Fatigue: feeling of tiredness or lack of energy. - Dizziness: light‑headed sensation, especially when standing. - Headache: mild to moderate cranial pain. - Nausea: feeling of queasiness or urge to vomit. - Insomnia: difficulty falling or staying asleep.

Serious or Rare Side Effects: - Severe hypotension: marked drop in blood pressure requiring medical attention. - Bradycardia: abnormally slow heart rate. - Hepatic dysfunction: abnormal liver enzyme elevations. - Allergic reactions: rash, pruritus, or angioedema. - Cardiac arrhythmia: irregular heart rhythm. - Syncope: sudden loss of consciousness.

Before initiating therapy with Moxostad, several safety considerations should be observed. - Blood pressure monitoring: regularly check to avoid excessive hypotension. - Renal impairment: dose may need adjustment in patients with reduced kidney function. - Hepatic impairment: use with caution; monitor liver function tests. - Concomitant diuretics: increased risk of volume depletion; monitor electrolytes. - Discontinuation: do not stop abruptly without medical advice to prevent rebound hypertension. - Store at room temperature: keep in the original container, protect from moisture and direct sunlight.

Moxostad can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Other central antihypertensives (e.g., clonidine): additive hypotensive effect. - Potent CYP2D6 inhibitors (e.g., fluoxetine): may increase plasma concentrations of moxonidine. - NSAIDs: can attenuate the antihypertensive response.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance the blood‑pressure‑lowering effect, requiring dose titration. - ACE inhibitors or ARBs: combined use may produce greater blood pressure reduction. - Alcohol: can increase dizziness and hypotension risk.